<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01837576</url>
  </required_header>
  <id_info>
    <org_study_id>LP0076-1016</org_study_id>
    <nct_id>NCT01837576</nct_id>
  </id_info>
  <brief_title>An Exploratory Psoriasis Plaque Test Study With Different Dose Combinations of Calcipotriol Plus Betamethasone Dipropionate in the Daivobet® Gel Vehicle in Psoriasis Vulgaris</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>LEO Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LEO Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the antipsoriatic effect of 5 different combinations
      of calcipotriol plus betamethasone dipropionate in Daivobet® gel vehicle in compared to
      Daivobet® gel in order to explore/find other safe and effective combination of the two
      components.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The absolute change in Total Clinical Score (TCS) of clinical symptoms (sum of erythema, scaling and infiltration)</measure>
    <time_frame>3 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absolute change in single clinical symptom score: erythema, scaling, infiltration at end of treatment and individual visits compared to baseline.</measure>
    <time_frame>3 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change in Total Clinical Score (TCS) at individual visits compared to baseline</measure>
    <time_frame>3 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The absolute change in total skin thickness and echopoor band thickness at end of treatment compared to baseline.</measure>
    <time_frame>3 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Psoriasis Vulgaris</condition>
  <arm_group>
    <arm_group_label>Calcipotriol plus BDP gel in different doses</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A-E: calcipotriol, BDP gel in different concentrations</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcipotriol plus BDP gel in different doses</intervention_name>
    <description>Topical , Once daily, 3 weeks</description>
    <arm_group_label>Calcipotriol plus BDP gel in different doses</arm_group_label>
    <other_name>Daivobet gel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject must provide written information.

          -  Age 18 years or above.

          -  Males, or females subjects.

          -  Subjects with lesions of psoriasis vulgaris located on arms and/or legs and/or trunk.

          -  Subjects with, in the opinion of the investigator, stable psoriasis

          -  Subjects with psoriasis lesions(plaques)assessed by a Total Clinical Score 4 to 9
             inclusive but each individual item ≥ 1.

          -  Subjects willing and able to follow all the study procedures and complete the whole
             study.

          -  Subjects affiliated to a social security system.

          -  Female of childbearing potential with a negative urine pregnancy test

        Exclusion Criteria:

          -  Female subjects who are pregnant, of childbearing potential and who wish to become
             pregnant during the study, or who are breast feeding.

          -  Systemic treatment with biological therapies within 4 weeks (etanercept), 2 months
             (adalimumab, alefacept, infliximab), 4 months (ustekinumab) or 4 weeks/5 halflives
             (whichever is longer) for experimental biological products prior to randomisation and
             during the study.

          -  Systemic treatments with all other therapies than biologicals, (e.g., corticosteroids,
             retinoids, immunosuppressants) within the 4 week period prior to randomisation and
             during the study.

          -  Subjects using one of the following topical drugs for the treatment of psoriasis prior
             to randomisation and during the study: Potent or very potent (WHO group III-IV)
             corticosteroids (4 weeks).

          -  Subjects using of phototherapy prior to randomisation and during the study:

          -  PUVA (4 weeks)

          -  UVB (2 weeks).

          -  Subjects using one of the following topical drugs for the treatment of psoriasis
             within two weeks prior to randomisation and during the study:

          -  WHO group I-II corticosteroids (except if used fortreatment of scalp and/or facial
             psoriasis),

          -  Topical retinoids, Vitamin D analogues, Topical immunomodulators (e.g. macrolides),
             Anthracen derivatives, Tar, Salicylic acid

          -  Subjects using emollients on the selected plaques within one week before randomisation
             and during the study.

          -  Initiation of, or expected changes to concomitant medication that may affect psoriasis
             vulgaris (e.g.,beta blockers, antimalarial drugs, lithium and ACE inhibitors) within 2
             weeks prior to the randomization and during the study.

          -  Subjects with current diagnosis of guttate, erythrodermic, exfoliative or pustular
             psoriasis.

          -  Subjects with known/suspected disorders of calcium metabolism associated with
             hypercalcemia within the last 10 years, based on medical history and/or subject
             interview.

          -  History of any severe disease or serious current condition which, in the opinion of
             the Investigator, would put the subject at risk by participating in the study or would
             interfere significantly with the evaluation of study results or the study course

          -  Subjects who have accepted biopsies with a positive Hepatitis B, Hepatitis C or HIV
             test

          -  Subjects who have received treatment with any non marketed drug substance within the 4
             week period prior to randomisation or longer, if the class of the substancerequires a
             longer washout as defined above

          -  Subjects with current participation in any other interventional clinical

          -  Subjects with known or suspected hypersensitivity to component(s) of the
             investigational products.

          -  Subjects with any concomitant medical or dermatological disorder(s) which might
             preclude accurate evaluation of the psoriasis on the test areas.

          -  Subjects foreseeing an intensive solar exposure during the study or having been
             exposed within two weeks preceding the screening visit.

          -  Subjects who have accepted the biopsies with any contraindication to skin biopsy
             procedures.

          -  Subjects impossible to contact in case of emergency.

          -  In the opinion of the investigator, subjects are unlikely to comply with the Clinical
             Study Protocol.

          -  Subjects who are in an exclusion period in the National Biomedical Research Register
             of the French Ministry of Health at randomization.

          -  Subject under guardianship, hospitalized in a public or private institution, for a
             reason other than the research or subject deprived of freedom.

          -  Subjects previously randomised in this trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Catherine Queille-Roussel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre de harmacologie Clinique Appliquée à la Dermatologie (CPCAD), 06202 Nice Cedex 3, France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre de harmacologie Clinique Appliquée à la Dermatologie (CPCAD)</name>
      <address>
        <city>Nice</city>
        <state>Nice Cedex 3</state>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 18, 2013</study_first_submitted>
  <study_first_submitted_qc>April 22, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 23, 2013</study_first_posted>
  <last_update_submitted>July 22, 2013</last_update_submitted>
  <last_update_submitted_qc>July 22, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 23, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Psoriasis Vulgaris</keyword>
  <keyword>Calcipotriol</keyword>
  <keyword>Betamethasone Dipropionate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Betamethasone-17,21-dipropionate</mesh_term>
    <mesh_term>Betamethasone benzoate</mesh_term>
    <mesh_term>Betamethasone</mesh_term>
    <mesh_term>Betamethasone Valerate</mesh_term>
    <mesh_term>Betamethasone sodium phosphate</mesh_term>
    <mesh_term>Calcipotriene</mesh_term>
    <mesh_term>Calcitriol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

